Prednisone tablets: Brand change

Brand change Active

The funded brand of prednisone tablets is changing from Apo-Prednisone to Prednisone Clinect.

New brand name, same medicine

The current brand, Apo-Prednisone, is changing to Prednisone Clinect. The medicine is still made by the same manufacturer. The tablets will look the same, contain the same ingredients and be available in the same strengths and pack sizes.

The brand change has come about because Apotex, who supplied Apo-Prednisone, are leaving the New Zealand market. Clinect has agreed to supply the New Zealand market with prednisone tablets. 

People taking prednisone tablets should not notice any difference with this change in brand.

Stock status

We expect Apo-Prednisone brand tablets to run out between now and April 2022. Different strengths will run out at a different rates. 

Once stock has run out, it will be replaced by the Prednisone Clinect brand. Until then, pharmacies and wholesalers can continue to order the Apo-Prednisone brand. 

Product details

Tab 1 mg

  • Apo-Prednisone | 665762 | $18.58 per 500
  • Prednisone Clinect | 2608715 | $18.58 per 500

Tab 2.5 mg

  • Apo-Prednisone | 695459 | $21.04 per 500
  • Prednisone Clinect | 2608723 | $21.04 per 500

Tab 5 mg - Up to 30 tab available on a PSO

  • Apo-Prednisone | 304328 | $19.30 per 500
  • Prednisone Clinect | 2608731 | $19.30 per 500 

Tab 20 mg - Up to 30 tab available on a PSO

  • Apo-Prednisone | 374466 | $50.51 per 500
  • Prednisone Clinect | 2608758 | $50.51 per 500

Schedule listing for prednisone(external link)

Key dates

1 December 2021: Prednisone Clinect brand of prednisone tab 1 mg, 2.5 mg. 5 mg and 20 mg fully funded.

1 November 2022: Apo-Prednisone brand of prednisone tablets de-listed from the Schedule.

Who to contact

If you use prenisone tablets, talk to your pharmacist or other trusted health professional. They can explain what this change means for you.

If you have questons about the funding for prednisone tablets, email enquiry@pharmac.govt.nz 

More about Apotex's departure from the New Zealand market